Nuvation Bio Inc.
NUVB
$4.39
-$0.11-2.44%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 633.06% | 1,704.68% | 236.79% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 633.06% | 1,704.68% | 236.79% | -- | -- |
| Cost of Revenue | -69.66% | 121.06% | 91.24% | -- | -- |
| Gross Profit | 2,614.78% | 1,339.97% | 2,464.77% | -- | -- |
| SG&A Expenses | 54.28% | 90.78% | 138.20% | 381.08% | 376.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.24% | 42.45% | 46.36% | 207.38% | 186.37% |
| Operating Income | 36.90% | -17.32% | -40.33% | -192.11% | -158.95% |
| Income Before Tax | 25.99% | -35.38% | 87.24% | -259.90% | -258.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 25.99% | -35.38% | 87.24% | -259.90% | -258.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 25.99% | -35.38% | 87.24% | -259.90% | -258.63% |
| EBIT | 36.90% | -17.32% | -40.33% | -192.11% | -158.95% |
| EBITDA | 37.65% | -16.61% | -40.30% | -191.42% | -158.58% |
| EPS Basic | 27.54% | -8.17% | 90.83% | -132.89% | -132.86% |
| Normalized Basic EPS | 27.59% | -8.18% | -13.30% | -132.94% | -132.15% |
| EPS Diluted | 27.54% | -8.17% | 90.83% | -128.57% | -132.86% |
| Normalized Diluted EPS | 27.59% | -8.18% | -13.30% | -132.94% | -132.15% |
| Average Basic Shares Outstanding | 2.20% | 25.16% | 39.23% | 54.58% | 53.86% |
| Average Diluted Shares Outstanding | 2.20% | 25.16% | 39.23% | 54.58% | 53.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |